Pharma Focus Asia

German Merck Plans US$107.67 million Plant in China

Merck KGaA plans to construct a new plant in China to manufacture diabetes drugs and address critical healthcare needs of the Chinese population.

Location

The new plant is planned to be built in Shaghai, China covering an area of 40,000 square meters. The plant will have a room for a 20,000-square-meter expansion.

Budget

The US$107.67 million (€80 million) plant will manufacture diabetes drugs namely Glucophage, Concor, Euthyrox and also drugs for heart and thyroid conditions.

Schedule

The construction work is scheduled to start in September 2014 and expected to be completed in 2016. Merck plans to start commercial production in 2017.

Specifications Table:

  • Company Name
  • Merck KGaA
  • Location
  • Shanghai, China
  • Construction Type
  • New PLant
  • Date of Start
  • September 2014
  • Date of Completion
  • 2016
  • Estimated Investment:
  • US$107.67 million (€80 million)
  • Key players
  • Sponsors/Partners
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference